(VIANEWS) – Neurocrine Biosciences (NBIX), Expedia Group (EXPE), Bank OZK (OZK) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Neurocrine Biosciences (NBIX)
24.6% sales growth and 10.77% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $1.9.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 73.56. Meaning, the purchaser of the share is investing $73.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.77%.
2. Expedia Group (EXPE)
10.8% sales growth and 21.12% return on equity
Expedia Group, Inc. operates as an online travel company in the United States and internationally. The company operates through B2C, B2B, and trivago segments. Its B2C segment includes Brand Expedia, a full-service online travel brand offers various travel products and services; Hotels.com for lodging accommodations; Vrbo, an online marketplace for the alternative accommodations; Orbitz, Travelocity, Wotif Group, ebookers, CheapTickets, Hotwire.com and CarRentals.com. The company's B2B segment provides various travel and non-travel companies including airlines, offline travel agents, online retailers, corporate travel management, and financial institutions who leverage its travel technology and tap into its diverse supply to augment their offerings and market Expedia Group rates and availabilities to its travelers. Its trivago segment, a hotel metasearch website, which send referrals to online travel companies and travel service providers from hotel metasearch websites. In addition, the company provides brand advertising through online and offline channels, loyalty programs, mobile apps, and search engine marketing, as well as metasearch, social media, direct and personalized traveler communications on its websites, and through direct e-mail communication with its travelers. The company was formerly known as Expedia, Inc. and changed its name to Expedia Group, Inc. in March 2018. Expedia Group, Inc. was founded in 1996 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Expedia Group has a trailing twelve months EPS of $5.31.
PE Ratio
Expedia Group has a trailing twelve months price to earnings ratio of 26.1. Meaning, the purchaser of the share is investing $26.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.12%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 140% and 23.9%, respectively.
Yearly Top and Bottom Value
Expedia Group’s stock is valued at $138.57 at 10:22 EST, way below its 52-week high of $160.05 and way higher than its 52-week low of $87.94.
Volume
Today’s last reported volume for Expedia Group is 594256 which is 77.97% below its average volume of 2698400.
3. Bank OZK (OZK)
7.3% sales growth and 14.05% return on equity
Bank OZK provides various retail and commercial banking services. The company accepts various deposit products, including non-interest-bearing checking, interest bearing transaction, business sweep, savings, money market, individual retirement, and other accounts, as well as time deposits. It also offers real estate, consumer and business purpose, indirect recreational vehicle and marine, commercial and industrial, government guaranteed, agricultural equipment, small business, lines of credit, homebuilder, and affordable housing loans; business aviation and subscription financing services; and mortgage and other lending products. In addition, the company provides trust and wealth services, such as personal trusts, custodial accounts, investment management accounts, and retirement accounts, as well as corporate trust services, including trustee, paying agent and registered transfer agent services, and other related services. Further, it offers treasury management services comprising automated clearing house, wire transfer, transaction reporting, wholesale lockbox, remote deposit capture, automated credit line transfer, reconciliation, positive pay, merchant and commercial card, and other services, as well as zero balance and investment sweep accounts. Additionally, the company provides ATMs; telephone, online, and mobile banking services; debit and credit cards; safe deposit boxes; and other products and services, as well as processes merchant debit and credit card transactions. The company was formerly known as Bank of the Ozarks and changed its name to Bank OZK in July 2018. Bank OZK was founded in 1903 and is headquartered in Little Rock, Arkansas.
Earnings Per Share
As for profitability, Bank OZK has a trailing twelve months EPS of $5.71.
PE Ratio
Bank OZK has a trailing twelve months price to earnings ratio of 7.32. Meaning, the purchaser of the share is investing $7.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.05%.
Previous days news about Bank OZK(OZK)
- According to Zacks on Wednesday, 14 February, "In January 2024, Bank OZK (OZK Quick QuoteOZK – Free Report) announced a hike in its quarterly dividend. "
4. Universal Health Services (UHS)
5.8% sales growth and 11.15% return on equity
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. The company also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Universal Health Services has a trailing twelve months EPS of $9.52.
PE Ratio
Universal Health Services has a trailing twelve months price to earnings ratio of 16.87. Meaning, the purchaser of the share is investing $16.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.15%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 29, 2024, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.5%.
Yearly Top and Bottom Value
Universal Health Services’s stock is valued at $160.60 at 10:22 EST, below its 52-week high of $164.96 and way above its 52-week low of $113.69.
Previous days news about Universal Health Services(UHS)
- According to Zacks on Wednesday, 14 February, "Some better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS Quick QuoteUHS – Free Report) , Integer Holdings Corporation (ITGR Quick QuoteITGR – Free Report) and Stryker (SYK Quick QuoteSYK – Free Report) ."
- According to Zacks on Tuesday, 13 February, "Some better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS Quick QuoteUHS – Free Report) , Integer Holdings Corporation (ITGR Quick QuoteITGR – Free Report) and DaVita (DVA Quick QuoteDVA – Free Report) ."
- According to Zacks on Monday, 12 February, "Headquartered in King of Prussia, PA, Universal Health Services operates acute care hospitals, behavioral health centers, surgical hospitals and radiation oncology centers and provides commercial health insurance services. "
